Patient Scenario Cont’d: Treatment in Late-Line Relapsed MM

Opinion
Video

Turning the focus back to the clinical scenario, Donna Catamero, ANP-BC, OCN, CCRC, discusses the patient’s repeat diagnostic workup and the panel provides their insights on treatment decisions.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.